BGB-15025 + Tislelizumab for Advanced Cancers
Trial Summary
What is the purpose of this trial?
This trial is testing a new drug, BGB-15025, alone and with an immune-boosting drug, tislelizumab, in patients with advanced cancer. The goal is to see if these treatments are safe and to find the best dose.
Do I have to stop taking my current medications for this trial?
The trial protocol does not specify if you need to stop taking your current medications. However, if you are on systemic corticosteroids or other immunosuppressive medications, you must stop them at least 14 days before the first dose of the study treatment.
What data supports the idea that BGB-15025 + Tislelizumab for Advanced Cancers is an effective treatment?
The available research shows that Tislelizumab, when used in combination with other treatments, has shown promising results in treating various advanced cancers. For example, in patients with advanced urothelial carcinoma, Tislelizumab demonstrated a 24% response rate, meaning nearly a quarter of patients saw their cancer shrink or disappear. Additionally, Tislelizumab has been compared to another drug, Pembrolizumab, for lung cancer treatment, and both showed similar effectiveness in improving patient outcomes. This suggests that Tislelizumab, including when combined with BGB-15025, could be an effective option for treating advanced cancers.12345
What safety data is available for BGB-15025 and Tislelizumab in treating advanced cancers?
Tislelizumab, an anti-PD-1 antibody, has been studied in various cancers and shows an acceptable safety profile. Common adverse effects include fatigue, anemia, and decreased neutrophil count, with serious events like respiratory infection or hepatic injury being rare. In combination with chemotherapy for non-small cell lung cancer, it was well tolerated with a safety profile similar to the overall population. In urothelial carcinoma, common treatment-related adverse events were anemia and pyrexia, with some grade 3-4 events like anemia and hyponatremia. Three deaths were possibly related to treatment. Overall, Tislelizumab demonstrates manageable safety in these studies.24567
Is the drug BGB-15025, Tislelizumab a promising treatment for advanced cancers?
Yes, Tislelizumab is a promising drug for advanced cancers. It has shown positive effects in treating various types of cancer, including lung, liver, and stomach cancers. It is designed to help the immune system fight cancer more effectively and has been approved for use in several countries. It also offers an economic advantage, making it a valuable option for cancer treatment.23458
Research Team
Xiusong Qiu, MD
Principal Investigator
BeiGene
Eligibility Criteria
This trial is for adults with advanced solid tumors, including lung, esophageal, or stomach cancers that have worsened after treatment or haven't been treated yet. They must be relatively healthy (ECOG ≤ 1) and have at least one tumor that can be measured. People who've had prior HPK1-targeted therapy or don't meet specific blood and organ function tests cannot join.Inclusion Criteria
Treatment Details
Interventions
- BGB-15025 (Other)
- Tislelizumab (PD-1 Inhibitor)
Find a Clinic Near You
Who Is Running the Clinical Trial?
BeiGene
Lead Sponsor